Who is eligible for clinical trial NCT06993233?

Participants must meet protocol criteria for Hidradenitis Suppurativa (HS). Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT06993233 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-05-20

A Study With CIT-013 in HS Patients (NCT06993233)

A Phase 2a Double Blind, Randomized, Parallel Arm, Placebo-controlled Trial to Investigate the Effects of Two Dose Levels of CIT-013 on Disease Activity in Patients With Hidradenitis Suppurativa

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Citryll BV

🩺 Plain-English Summary (8th-Grade Level)

The goal of this clinical trial is to learn if CIT-013 works to treat Hidradenitis Suppurativa in adults. It will also learn about the safety of CIT-013. The main questions it aims to answer are: Does CIT-013 lower the disease activity of HS patients? What medical problems do participants have when receiving CIT-013? Researchers will compare CIT-013 to a placebo (a look-alike substance that contains no drug) to see if CIT-013 works to treat the symptoms of HS. Participants will: Take receive 50 or 100 mg CIT-013 or placebo every other week for 12 weeks Visit the clinic once every 2 weeks for checkups and tests Keep monitor their symptoms during this period

Who can join: Review the eligibility criteria below.

Location: CA-01 — Barrie

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (28 Sites)

Showing the first 25 of 28 sites.

CA-01 — Barrie,
CA-05 — Calgary,
CA-02 — London,
CA-04 — Newmarket,
CA-03 — Winnipeg,
DE-06 — Bad Bentheim,
DE-01 — Bochum,
DE-04 — Dresden,
DE-02 — Frankfurt,
DE-08 — Kiel,
DE-03 — Oldenburg,
Erasmus UMC — Rotterdam,
PL-06 — Bialystok,
PL-08 — Gdansk,
PL-03 — Katowice,
PL-02 — Lodz,
PL-10 — Lodz,
PL-09 — Poznan,
PL-01 — Rzeszów,
PL-05 — Wroclaw,
ES-05 — Barcelona,
ES-04 — Madrid,
ES-02 — Santiago de Compostela,
ES-03 — Seville,
ES-01 — Valencia,

📞 Contact the Study Coordinator

Phone: +31613328444

Email: lmiddelink@citryll.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hidradenitis Suppurativa (HS)

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense — Phoenix, Arizona
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa — Phoenix, Arizona
Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa — Missouri City, Texas
A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) — Irvine, California
A Study to Evaluate the Efficacy of Botulinum Toxin in Patients With Hidradenitis Suppurativa — Worcester, Massachusetts
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa — Chapel Hill, North Carolina

Explore by condition: All Hidradenitis Suppurativa (HS) clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗